Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Chronic Spontaneous Urticaria · Asthma

Novartis India

Novartis Pharmaceuticals

Novartis India clinical programs — 341 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Mumbai, IN HQ
1996 Founded
2,240 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Mumbai, IN
Founded
1996
Employees
2,240
Programs
341
Drugs
317
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Programs

Novartis India projects

341 ClinicalTrials.gov programs sponsored by Novartis India.

Novartis India has 341 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

341 programs

Clinical programs

Page 7 of 8

  1. CLTP001A12101

    Novartis Pharmaceuticals

    Healthy volunteers

    phase 1 other active

    1 trial

  2. COJR520A12101

    Novartis Pharmaceuticals

    Chronic Kidney Disease

    phase 1 other active

    1 trial

  3. CPDR001X2X01B

    Novartis Pharmaceuticals

    Different types of advanced cancer

    phase 1 small molecule active

    1 trial

  4. CPIT565B12101

    Novartis Pharmaceuticals

    Systemic Lupus Erythematosus

    phase 1 other active

    1 trial

  5. CPIT565C12101

    Novartis Pharmaceuticals

    Rheumatoid Arthritis

    phase 1 other active

    1 trial

  6. CTNO155X2101

    Novartis Pharmaceuticals

    Advanced solid tumors

    phase 1 other active

    1 trial

  7. CVAY736J12101

    Novartis Pharmaceuticals

    Relapsed/refractory Non Hodgkin Lymphoma

    phase 1 other active

    1 trial

  8. INC280 single agent

    Novartis Pharmaceuticals

    Non-Small Cell Lung Cancer

    phase 1 small molecule terminated

    1 trial

  9. Imatinib/Acetaminophen

    Novartis Pharmaceuticals

    Chronic Myeloid Leukemia (CML)

    phase 1 small molecule completed

    1 trial

  10. Indacaterol (QAB149)

    Novartis Pharmaceuticals

    Healthy

    phase 1 small molecule completed

    1 trial

  11. JSB462

    Novartis Pharmaceuticals

    Metastatic Prostate Cancer (mCRPC)

    phase 1 small molecule active

    1 trial

  12. KFA115

    Novartis Pharmaceuticals

    Carcinoma, Non-Small-Cell Lung

    phase 1 small molecule active

    1 trial

  13. LDK378

    Novartis Pharmaceuticals

    Anaplastic Lymphoma Kinase (ALK)

    phase 1 small molecule completed

    1 trial

  14. LDT600 (Telbivudine)

    Novartis Pharmaceuticals

    Chronic Hepatitis B

    phase 1 small molecule completed

    1 trial

  15. LEE011

    Novartis Pharmaceuticals

    Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer

    phase 1 small molecule completed

    1 trial

  16. LGH447

    Novartis Pharmaceuticals

    Relapsed and Refractory Multiple Myeloma

    phase 1 small molecule completed

    1 trial

  17. LGH447

    Novartis Pharmaceuticals

    AML and High Risk MDS

    phase 1 small molecule completed

    1 trial

  18. MBG453

    Novartis Pharmaceuticals

    Myelodysplastic Syndromes

    phase 1 small molecule terminated

    1 trial

  19. NIO752B12201

    Novartis Pharmaceuticals

    Alzheimer’s Disease

    phase 1 other active

    1 trial

  20. PDR001

    Novartis Pharmaceuticals

    Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma

    phase 1 mab completed

    1 trial

  21. PDR001

    Novartis Pharmaceuticals

    Non-small Cell Lung Cancer

    phase 1 small molecule terminated

    1 trial

  22. Phase I study of MGY825 in patients with lung cancer

    Novartis Pharmaceuticals

    Advanced non-small cell lung cancer with or without NFE2L2/KEAP1/CUL3 mutations in adult patients

    phase 1 other active

    1 trial

  23. QEQ278

    Novartis Pharmaceuticals

    Carcinoma, Non-Small-Cell Lung

    phase 1 mab terminated

    1 trial

  24. Study of PIT565 in relapsed and/or refractory B-cell malignancies

    Novartis Pharmaceuticals

    Relapsed and/or refractory B-cell Non-Hodgkin lymphoma (R/R B-NHL) and relapsed and/or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL)

    phase 1 other active

    1 trial

  25. Aliskiren

    Novartis Pharmaceuticals

    Hypertension

    approved small molecule completed

    1 trial

  26. CAIN457I2401

    Novartis Pharmaceuticals

    non-radiographic axial spondyloarthritis

    approved small molecule active

    1 trial

  27. CDRB436G2401

    Novartis Pharmaceuticals

    Children and Adolescents with Cancers Harboring V600 mutation.

    approved small molecule active

    1 trial

  28. CDRB436X2X02B

    Novartis Pharmaceuticals

    Multiple indications

    approved small molecule active

    1 trial

  29. CELC200A2406

    Novartis Pharmaceuticals

    Parkinson's Disease

    approved small molecule completed

    1 trial

  30. CERITINIB

    Novartis Pharmaceuticals

    non small cell lung cancer

    approved small molecule active

    1 trial

  31. CINC424A2X01B

    Novartis Pharmaceuticals

    This study is designed to accept patients with varied disease origins, depending on the parent protocol

    approved small molecule active

    1 trial

  32. CKJX839A12402

    Novartis Pharmaceuticals

    Hypercholesterolemia

    approved small molecule active

    1 trial

  33. CKJX839A1DE02

    Novartis Pharmaceuticals

    Hypercholesterolemia

    approved small molecule active

    1 trial

  34. CLEE011A2412B

    Novartis Pharmaceuticals

    HR+, HER2- advanced or metastatic breast cancer

    approved small molecule active

    1 trial

  35. CLNP023A2002B

    Novartis Pharmaceuticals

    IgA Nephropathy

    approved small molecule active

    1 trial

  36. Enteric-Coated Mycophenolate Sodium (EC-MPS)

    Novartis Pharmaceuticals

    Renal Transplant

    approved small molecule completed

    1 trial

  37. Fluvirin(TIVf)

    Novartis Pharmaceuticals

    Influenza

    approved mab completed

    1 trial

  38. IPTACOPAN HYDROCHLORIDE, IPTACOPAN

    Novartis Pharmaceuticals

    C3 Glomerulopathy or idiopathic immune-complex membranoproliferative glomerulonephritis

    approved small molecule active

    1 trial

  39. Indacaterol

    Novartis Pharmaceuticals

    Chronic Obstructive Pulmonary Disease

    approved small molecule completed

    1 trial

  40. Kesimpta 20 mg solution for injection in pre-filled syringe

    Novartis Pharmaceuticals

    Relapsing forms of Multiple Sclerosis (RMS)

    approved small molecule active

    1 trial

  41. Neovascular Age-related Macular Degeneration

    Novartis Pharmaceuticals

    Neovacular Age-related Macular Degeneration

    approved other completed

    1 trial

  42. Ofatumumab

    Novartis Pharmaceuticals

    Relapsing Multiple Sclerosis

    approved mab completed

    1 trial

  43. Placebo of vildagliptin

    Novartis Pharmaceuticals

    Type 2 Diabetes Mellitus

    approved small molecule completed

    1 trial

  44. Pluvicto 1 000 MBq/mL solution for injection/infusion

    Novartis Pharmaceuticals

    Prostate cancer

    approved small molecule active

    1 trial

  45. Ribociclib

    Novartis Pharmaceuticals

    Metastatic Breast Cancer

    approved small molecule active

    1 trial

  46. Rivastigmine

    Novartis Pharmaceuticals

    Alzheimer's Disease

    approved small molecule completed

    1 trial

  47. Rivastigmine transdermal patch

    Novartis Pharmaceuticals

    Alzheimer's Disease

    approved small molecule completed

    1 trial

  48. SEG101

    Novartis Pharmaceuticals

    Sickle cell disease

    approved small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Novartis India have?

341 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.